Browsing ICR Divisions by author "Huang, Paul"
Now showing items 61-72 of 72
-
The adequacy of tissue microarrays in the assessment of inter- and intra-tumoural heterogeneity of infiltrating lymphocyte burden in leiomyosarcoma.
Lee, ATJ; Chew, W; Wilding, CP; Guljar, N; Smith, MJ; et al. (NATURE PORTFOLIO, 2019-10-10)The characterisation and clinical relevance of tumour-infiltrating lymphocytes (TILs) in leiomyosarcoma (LMS), a subtype of soft tissue sarcoma that exhibits histological heterogeneity, is not established. The use of tissue ... -
The biology and treatment of leiomyosarcomas.
Kerrison, WGJ; Thway, K; Jones, RL; Huang, PH (ELSEVIER SCIENCE INC, 2023-04-01)Leiomyosarcoma (LMS) is a soft tissue sarcoma of smooth muscle origin that can arise in multiple anatomical sites and is broadly classified as extra-uterine LMS or uterine LMS. There is substantial interpatient heterogeneity ... -
The evolving management of epithelioid sarcoma.
Alves, A; Constantinidou, A; Thway, K; Fisher, C; Huang, P; et al. (2021-07-18) -
The Extracellular Matrix in Soft Tissue Sarcomas: Pathobiology and Cellular Signalling.
Pankova, V; Thway, K; Jones, RL; Huang, PH (FRONTIERS MEDIA SA, 2021-12-09)Soft tissue sarcomas are rare cancers of mesenchymal origin or differentiation comprising over 70 different histological subtypes. Due to their mesenchymal differentiation, sarcomas are thought to produce and deposit large ... -
The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib.
Wilding, CP; Elms, ML; Judson, I; Tan, A-C; Jones, RL; et al. (TAYLOR & FRANCIS LTD, 2019-10-30)Introduction: Tyrosine kinases are key mediators of intracellular signaling cascades and aberrations in these proteins have been implicated in driving oncogenesis through the dysregulation of fundamental cellular processes ... -
The perplexing role of immuno-oncology drugs in osteosarcoma.
Smrke, A; Tam, YB; Anderson, PM; Jones, RL; Huang, PH (ELSEVIER, 2021-12-01)Osteosarcoma is a rare, primary tumour of bone. Curative treatment consists of multi-agent chemotherapy and complete surgical resection. Despite the use of multi-agent chemotherapy, the risk of recurrence is high. Survival ... -
The proteomic landscape of soft tissue sarcomas.
Burns, J; Wilding, CP; Krasny, L; Zhu, X; Chadha, M; et al. (NATURE PORTFOLIO, 2023-06-29)Soft tissue sarcomas (STS) are rare and diverse mesenchymal cancers with limited treatment options. Here we undertake comprehensive proteomic profiling of tumour specimens from 321 STS patients representing 11 histological ... -
Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model.
Maguire, SL; Peck, B; Wai, PT; Campbell, J; Barker, H; et al. (WILEY, 2016-11-01)The initiation and progression of breast cancer from the transformation of the normal epithelium to ductal carcinoma in situ (DCIS) and invasive disease is a complex process involving the acquisition of genetic alterations ... -
Translational Aspects of Epithelioid Sarcoma: Current Consensus.
Grünewald, TGP; Postel-Vinay, S; Nakayama, RT; Berlow, NE; Bolzicco, A; et al. (AMER ASSOC CANCER RESEARCH, 2024-03-15)Epithelioid sarcoma (EpS) is an ultra-rare malignant soft-tissue cancer mostly affecting adolescents and young adults. EpS often exhibits an unfavorable clinical course with fatal outcome in ∼50% of cases despite aggressive ... -
Tropomyosin receptor kinase inhibitors in the management of sarcomas.
Wilding, CP; Loong, HH; Huang, PH; Jones, RL (LIPPINCOTT WILLIAMS & WILKINS, 2020-06-05)PURPOSE OF REVIEW: Genetic aberrations resulting in tropomyosin receptor kinase (TRK) fusion proteins can drive oncogenesis and are postulated to occur in up to 1% of solid tumours. However, TRK fusions in adult sarcomas ... -
Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients-A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN).
Kasper, B; Achee, A; Schuster, K; Wilson, R; van Oortmerssen, G; et al. (MDPI, 2021-02-20)As leiomyosarcoma patients are challenged by the development of metastatic disease, effective systemic therapies are the cornerstone of outcome. However, the overall activity of the currently available conventional systemic ... -
Virtual Biopsy in Soft Tissue Sarcoma. How Close Are We?
Arthur, A; Johnston, EW; Winfield, JM; Blackledge, MD; Jones, RL; et al. (FRONTIERS MEDIA SA, 2022-07-01)A shift in radiology to a data-driven specialty has been unlocked by synergistic developments in imaging biomarkers (IB) and computational science. This is advancing the capability to deliver "virtual biopsies" within ...